Results 181 to 190 of about 7,802,667 (305)

The challenges in establishing and Upholding an adult Level III epilepsy center in an underserved area in the United states. [PDF]

Epilepsy Behav Rep
Dao KT, Chacko C, Braich S, Liu L, Zalmay N, Nguyen C, Radhakrishnan K, Liu CY, Kunhi-Veedu HP.   +8 more
europepmc   +1 more source

Patients in Iowa Counties Lacking Hospitals With Labor and Delivery Services Disproportionately Receive Care at Level III Maternal Care Hospitals When Undergoing Cesarean Delivery: A Retrospective Longitudinal Study. [PDF]

Cureus, 2022
Thenuwara KN, Dexter F, Ledolter J, Radke SM, Epstein RH.   +4 more
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Improving Skin-to-Skin Care Among Stable Infants in a Level III NICU: A Quality Improvement Project Using Kotter's Change Management Model. [PDF]

Cureus
Lati I, Carrasquilla-Lopez V, Chakravorty B, Bhutada A, Khan M.   +4 more
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Antimicrobial Consumption and Resistance of Restricted Antibiotics in a Level III Government Hospital. [PDF]

Acta Med Philipp
Abeleda MA, Peña I, Salenga R, Capule F, Nacabu-An SM, Nala P.   +5 more
europepmc   +1 more source

Who Needs Level III Lymph Node Dissection in Carcinoma Breast-Study from a Tertiary Care Center. [PDF]

Indian J Surg Oncol, 2023
Suresh GM, Yeshwanth R, Arjunan R, Ramachandra C, Altaf S.   +4 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Risk factors for cervical lymph node metastasis at different lateral levels in papillary thyroid cancer: level III as the central hub. [PDF]

Gland Surg
Zhang Y, Ji X, Zhang X, Wang Y.
europepmc   +1 more source

Update of antimicrobial resistance in level III and IV health institutions in Colombia between January 2018 and December 2021 [PDF]

Biomedica, 2023
De La Cadena E, Pallares CJ, García-Betancur JC, Porras JA, Villegas MV.   +4 more
europepmc   +1 more source